RALES (trial)
Pharmaceutical clinical trial / From Wikipedia, the free encyclopedia
The Randomized Aldactone Evaluation Study (RALES) trial is a landmark clinical study that assessed the impact of spironolactone, an aldosterone antagonist, on morbidity and mortality in patients with severe heart failure due to systolic dysfunction.[1] The findings from this trial significantly influenced the treatment guidelines for heart failure.
![]() | The topic of this article may not meet Wikipedia's general notability guideline. (July 2024) |
Quick Facts Randomized Aldactone Evaluation Study, Study type ...
Randomized Aldactone Evaluation Study | |
---|---|
Study type | randomized controlled trial |
Published | 1999 |
Article | Pitt, Bertram; et al. (2 September 1999). "The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure". New England Journal of Medicine. 341 (10): 709–717. doi:10.1056/NEJM199909023411001. PMID 10471456. |
Close